Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.

Scientists use patient-derived breast cancer organoids—or 3D mini-tumors—to study processes involved in slowing or stopping tumor growth, also known as cellular senescence.

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...